Skip to main content
. 2017 Mar 30;50(1):222–238. doi: 10.4143/crt.2017.093

Table 2.

Five-year relative survival rates of lymphoid malignancies by age group in Korea

Site Age (yr) Year
1993-1997
 1998-2002
 2003-2007
 2008-2012
Cases Relative survival Cases Relative survival Cases Relative survival Cases Relative survival
Hodgkin’s lymphoma Total 473 71.1 649 72.9 862 79.1 1,135 83.0
0-14 39 87.4 49 94.0 64 95.4 60 91.7
15-34 167 83.1 226 88.8 306 89.8 420 93.4
35-49 108 78.5 138 75.2 176 86.4 192 93.3
50-64 100 53.3 141 58.3 180 74.4 247 80.0
65-79 55 43.6 87 42.7 118 45.2 189 55.5
≥ 80 < 5 - 8 - 18 - 27 37.0
 Hodgkin’s lymphoma, nodular lymphocyte predominant Total < 5 - 17 - 17 - 30 92.5
 Classical Hodgkin’s lymphoma Total 469 71.0 632 72.8 845 79.0 1,105 82.7
0-14 39 87.4 49 94.0 64 95.4 59 91.6
15-34 167 83.1 223 88.7 299 89.6 409 93.2
35-49 106 78.1 131 73.8 175 86.3 184 93.8
50-64 98 53.3 136 58.9 173 74.4 239 80.2
65-79 55 43.6 85 42.4 116 44.8 187 54.5
≥ 80 < 5 - 8 - 18 - 27 37.0
Mature B-cell neoplasms Total 4,339 42.8 8,413 47.9 13,590 58.7 19,601 63.8
0-14 136 67.8 188 81.5 213 79.9 262 87.1
15-34 495 57.7 704 68.8 996 84.8 1,164 87.6
35-49 889 54.3 1,702 62.6 2,656 76.1 3,454 81.3
50-64 1,676 40.3 3,097 47.0 4,602 62.3 6,638 69.9
65-79 1,057 26.8 2,457 31.7 4,530 41.1 6,930 48.4
≥ 80 86 28.4 265 21.1 593 25.2 1,153 29.6
 Chronic lymphocytic leukemia/Small lymphocytic lymphoma Total 306 53.1 414 53.7 469 63.0 601 73.7
0-14 14 - < 5 - 0 - < 5 -
15-34 24 - 15 - < 5 - 9 -
35-49 58 70.4 67 70.0 49 82.7 67 89.2
50-64 111 57.0 156 58.5 163 67.3 199 88.0
65-79 89 30.4 146 45.9 225 58.0 277 63.3
≥ 80 10 - 26 6.6 28 41.4 47 45.3
 Immunoproliferative diseases Total 40 41.3 60 37.4 94 60.7 153 54.0
 Mantle cell lymphoma Total 40 60.8 118 53.0 237 41.4 355 52.4
0-14 < 5 - 0 - 0 - 0 -
15-34 5 - 8 - 5 - < 5 -
35-49 8 - 22 - 32 66.6 34 75.7
50-64 12 - 53 45.9 91 43.9 138 54.1
65-79 13 - 34 45.4 99 27.4 154 49.6
≥ 80 < 5 - < 5 - 10 - 27 0.0
 Follicular lymphoma Total 298 64.5 338 71.4 419 79.8 706 88.3
0-14 7 - 7 - < 5 - < 5 -
15-34 55 69.6 39 85.0 53 100.3 67 93.6
35-49 80 71.6 103 84.7 117 81.4 207 95.1
50-64 101 62.2 111 67.5 155 79.8 250 91.0
65-79 51 57.8 70 49.8 84 63.2 161 74.6
≥ 80 < 5 - 8 - 7 - 17 -
 Diffuse large B-cell lymphoma Total 2,213 49.5 4,413 52.9 6,377 59.1 8,574 61.5
0-14 60 68.5 82 81.8 69 79.8 88 84.9
15-34 347 55.4 499 65.6 538 80.6 611 81.5
35-49 519 57.6 980 63.7 1,303 72.6 1,456 77.6
50-64 783 49.0 1,532 53.7 2,058 64.2 2,701 70.2
65-79 461 34.5 1,165 37.1 2,089 43.7 3,116 47.2
≥ 80 43 36.5 155 28.8 320 23.0 602 27.1
 Burkitt’s lymphoma/Leukemia Total 81 52.6 168 66.4 364 57.8 439 62.8
0-14 47 70.3 90 83.4 126 79.4 155 87.0
15-34 15 - 24 - 72 55.7 73 80.9
35-49 5 - 15 - 49 59.8 81 47.8
50-64 10 - 24 - 77 44.5 66 38.0
65-79 < 5 - 13 - 36 12.6 58 24.3
≥ 80 < 5 - < 5 - < 5 - 6 -
 Marginal zone lymphoma Total 59 90.3 548 85.7 2,165 95.0 3,808 98.2
0-14 0 - < 5 - 10 - 10 -
15-34 16 - 79 92.8 279 97.8 364 99.2
35-49 15 - 174 90.2 687 97.9 1,095 99.1
50-64 21 - 188 88.2 747 96.6 1,513 97.9
65-79 7 - 96 68.9 415 85.0 754 97.7
≥ 80 0 - 7 - 27 86.5 72 89.3
 B-Cell prolymphocytic leukemia Total 0 - 0 - 6 - 25 57.0
 Hairy cell leukemia Total 11 - 13 - 16 - 26 69.8
 Plasma cell neoplasms Total 1,291 20.2 2,341 23.7 3,443 32.6 4,914 36.9
0-14 < 5 - < 5 - < 5 - < 5 -
15-34 30 57.1 37 62.5 40 85.3 35 82.1
35-49 194 29.5 326 37.1 401 50.6 498 52.0
50-64 621 20.2 1,009 25.2 1,275 38.4 1,714 44.2
65-79 417 12.2 904 16.1 1,538 23.1 2,301 29.5
≥ 80 27 22.8 64 6.0 186 11.9 365 18.8
Mature T-cell and NK-cell neoplasms Total 442 46.4 1,275 46.4 2,267 44.6 2,979 50.4
0-14 32 56.4 51 82.4 104 67.4 94 74.8
15-34 89 56.5 218 57.1 364 60.1 408 74.3
35-49 126 46.8 322 52.1 554 50.6 667 60.3
50-64 126 43.0 384 40.1 672 43.1 873 48.4
65-79 59 32.8 272 34.7 505 26.6 791 32.8
≥ 80 10 - 28 24.5 68 15.1 146 23.4
 T lymphoma cutaneous Total 63 59.8 128 72.6 217 82.5 419 87.7
0-14 < 5 - 7 - 13 - 21 -
15-34 11 - 31 77.7 58 88.2 107 95.6
35-49 21 - 32 72.7 66 82.8 115 92.7
50-64 15 - 30 69.7 49 84.6 95 91.6
65-79 10 - 27 64.2 26 61.6 67 69.6
≥ 80 < 5 - < 5 - 5 - 14 -
 Other T and NK-cell lymphomas Total 379 44.2 1,147 43.5 2,050 40.5 2,560 44.2
0-14 29 51.9 44 79.6 91 62.7 73 67.3
15-34 78 51.6 187 53.7 306 54.8 301 66.7
35-49 105 46.5 290 49.8 488 46.3 552 53.6
50-64 111 41.2 354 37.5 623 39.9 778 43.0
65-79 49 31.7 245 31.5 479 24.6 724 29.4
≥ 80 7 - 27 25.3 63 13.4 132 24.8
Precursor cell neoplasms Total 2,111 41.5 2,489 48.7 2,517 52.8 2,691 56.3
0-14 1,161 61.6 1,286 71.3 1,254 77.8 1,189 82.7
15-34 524 21.7 618 32.5 563 39.7 595 50.1
35-49 203 13.0 289 21.0 321 24.6 407 33.0
50-64 164 9.0 175 15.0 221 15.9 307 20.7
65-79 57 6.8 113 3.2 142 6.2 174 13.5
≥ 80 < 5 - 8 - 16 - 19 -
 Lymphoblastic lymphoma Total 101 43.0 222 45.8 249 51.8 294 54.4
0-14 44 59.2 88 66.0 92 75.1 86 75.2
15-34 35 31.6 91 36.4 93 47.5 113 54.4
35-49 11 - 23 - 24 - 48 43.2
50-64 8 - 11 - 28 29.9 23 -
65-79 < 5 - 9 - 9 - 21 -
≥ 80 0 - 0 - < 5 - < 5 -
 Lymphoblastic leukemia Total 2,010 41.4 2,267 49.0 2,268 52.9 2,397 56.5
0-14 1,117 61.7 1,198 71.6 1,162 78.1 1,103 83.3
15-34 489 21.0 527 31.8 470 38.2 482 49.2
35-49 192 12.2 266 19.8 297 25.2 359 31.6
50-64 156 7.4 164 15.3 193 13.9 284 20.9
65-79 54 7.2 104 2.4 133 6.6 153 11.0
≥ 80 < 5 - 8 - 13 - 16 -
Composite Hodgkin’s and non-Hodgkin’s lymphoma Total 0 - < 5 - < 5 - 6 -
Unknown type lymphoid neoplasm Total 3,227 47.1 2,957 52.7 1,935 52.1 1,435 50.2
0-14 168 60.3 124 72.7 69 75.5 27 84.2
15-34 522 52.8 369 65.6 194 76.5 98 81.4
35-49 698 58.9 649 67.2 357 70.3 202 78.0
50-64 1,064 45.6 897 54.5 507 60.7 329 66.2
65-79 713 31.2 784 32.8 619 33.2 551 35.8
≥ 80 62 21.3 134 23.0 189 16.8 228 13.5
All lymphoid malignancies Total 10,592 45.3 15,784 49.9 21,173 56.7 27,847 61.7
0-14 1,536 62.5 1,698 73.5 1,704 78.0 1,632 83.3
15-34 1,797 48.1 2,135 58.6 2,423 70.6 2,686 78.0
35-49 2,024 52.6 3,101 59.2 4,066 68.5 4,924 74.8
50-64 3,130 40.9 4,694 47.0 6,182 58.7 8,394 66.0
65-79 1,941 28.5 3,713 31.5 5,914 38.2 8,637 45.6
≥ 80 164 25.4 443 21.1 884 22.4 1,574 26.6

-, statistic not displayed due to less than 25 cases; NK, natural killer.